{"entity":{"id":"nct04793958","kind":"trial","name":"Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)","aka":[],"tldr":"A phase 3 trial of Cetuximab in colorectal cancer, run by Mirati Therapeutics Inc., active and no longer recruiting.","summary":"Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10) is a phase 3 interventional study registered as NCT04793958 by Mirati Therapeutics Inc., with 461 participants enrolled, started 2021-06-24 and due to reach its primary completion in 2026-01-16. Interventions recorded: MRTX849, Cetuximab, mFOLFOX6 Regimen, FOLFIRI Regimen. Conditions listed: Advanced Colorectal Cancer, Metastatic Colorectal Cancer. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04793958","url":"https://clinicaltrials.gov/study/NCT04793958"}],"tags":["ctgov-ingest"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":["cetuximab"],"companies":["bms"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04793958","phase":"3","setting":"A Randomized Phase 3 Study of MRTX849 in Combination With Cetuximab Versus Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation With Disease Progression On or After Standard First-Line Therapy","sponsor":"Mirati Therapeutics Inc.","enrolled":461,"outcomes":[]},"route":"/trials/nct04793958/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"drug":[{"id":"cetuximab","kind":"drug","name":"Cetuximab","route":"/drugs/cetuximab/"}],"company":[{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/"}]}}